Gabelli Funds LLC Has $8.65 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Gabelli Funds LLC cut its Thermo Fisher Scientific stake by 39.5% in the fourth quarter, selling 9,745 shares and leaving it with 14,920 shares worth about $8.65 million.
• Thermo Fisher reported solid quarterly results, with EPS of $5.44 beating estimates and revenue of $11.01 billion topping expectations, while also raising its quarterly dividend to $0.47 per share.
• Analysts remain mostly positive on TMO, with the stock carrying a “Moderate Buy” consensus and an average price target of $616.10, even as some firms trimmed their targets recently.

Gabelli Funds LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 39.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,920 shares of the medical research company's stock after selling 9,745 shares during the period. Gabelli Funds LLC's holdings in Thermo Fisher Scientific were worth $8,645,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in TMO. Brighton Jones LLC increased its position in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after acquiring an additional 988 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $170,000. Raymond James Financial Inc. increased its position in shares of Thermo Fisher Scientific by 7.4% during the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company's stock worth $315,781,000 after acquiring an additional 53,542 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company's stock worth $244,099,000 after acquiring an additional 2,262 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $63,499,170. This represents a 3.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company's stock, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Analyst Ratings Changes

TMO has been the subject of several recent research reports. Citigroup boosted their target price on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a "buy" rating in a research report on Friday, January 30th. Wells Fargo & Company decreased their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research report on Friday, May 8th. TD Cowen reduced their price objective on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a research report on Friday, January 30th. Morgan Stanley reaffirmed an "overweight" rating and issued a $620.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Finally, UBS Group reaffirmed a "neutral" rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $616.10.

Thermo Fisher Scientific Trading Up 1.4%

Shares of TMO stock opened at $448.34 on Wednesday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The company has a 50-day simple moving average of $483.39 and a two-hundred day simple moving average of $540.37. The company has a market capitalization of $166.61 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 1.96 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the prior year, the firm posted $5.15 EPS. The firm's quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were given a dividend of $0.47 per share. The ex-dividend date of this dividend was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's payout ratio is currently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.